Sam Aiyad Ali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sam Aiyad Ali has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Finn Gustafsson
Department of Cardiology Rigshospitalet Copenhagen Denmark
3 shared publications - Jawad Haider Butt
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; Department of Cardiology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
3 shared publications - Christian Selmer
Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark
2 shared publications - Emil Loldrup Fosbøl
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital , Blegdamsvej 9, Copenhagen 2100
2 shared publications - Lars Køber
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
2 shared publications - Lucas Malta Westergaard
Department of Cardiology Rigshospitalet University of Copenhagen Copenhagen Denmark
2 shared publications
Latest Publications
- Open Access
- 26 May 2026
- Published by Wiley in Journal of Internal Medicine
- Vol. 300 (2) , 204-212
Amiodarone‐related thyroid dysfunction and associated outcomes in patients with heart failure—A nationwide cohort study
Aim: Amiodarone increases the risk of thyroid dysfunction, but the prognostic significance of this complication in patients with heart failure (HF) is uncertain. This study investigates the association between amiodarone‐related thyroid dysfunction and risk of HF hospitalization or death in a nationwide cohort. Methods: Cases and controls were identified from a source population of all HF patients who initiated treatment with amiodarone from 1996 to 2021. Patients diagnosed with and/or treated for thyroid dysfunction within 3 years of starting amiodarone were classified as cases and comprised the study population together with controls matched 1:2 based on age, sex, calendar year, and HF duration. The primary outcome was a composite of HF hospitalization and death within 1 year from onset of thyroid dysfunction, analyzed using Kaplan–Meier curves and Cox regression models adjusted for comorbidities. Results: Of 21,947 HF patients who initiated amiodarone, 2972 (14%) developed thyroid dysfunction. After matching, the study population consisted of 2953 cases and 5857 controls, mean age 70 years, and 65% men. At 1‐year follow‐up the primary outcome occurred in 1154 (39%) cases and 1826 (31%) matched controls, yielding an adjusted hazard ratio (HR) of 1.30 (95% CI 1.21–1.40). This increased risk was observed for both HF hospitalization (30% vs. 23%, HR 1.35 [1.24–1.47]) and all‐cause death (19% vs. 15%, HR 1.21 [1.08–1.34]). Conclusions: In this nested case–control study derived from a nationwide cohort of amiodarone‐treated HF patients, new‐onset thyroid dysfunction was associated with a 30% higher risk of a composite of HF hospitalization and death within 1 year.
- 26 May 2026
- Published by Wiley in Journal of Internal Medicine
- Vol. 300 (2) , 204-212
Open AccessAmiodarone‐related thyroid dysfunction and associated outcomes in patients with heart failure—A nationwide cohort study
Aim: Amiodarone increases the risk of thyroid dysfunction, but the prognostic significance of this complication in patients with heart failure (HF) is uncertain. This study investigates the association between amiodarone‐related thyroid dysfunction and risk of HF hospitalization or death in a nationwide cohort. Methods: Cases and controls were identified from a source population of all HF patients who initiated treatment with amiodarone from 1996 to 2021. Patients diagnosed with and/or treated for thyroid dysfunction within 3 years of starting amiodarone were classified as cases and comprised the study population together with controls matched 1:2 based on age, sex, calendar year, and HF duration. The primary outcome was a composite of HF hospitalization and death within 1 year from onset of thyroid dysfunction, analyzed using Kaplan–Meier curves and Cox regression models adjusted for comorbidities. Results: Of 21,947 HF patients who initiated amiodarone, 2972 (14%) developed thyroid dysfunction. After matching, the study population consisted of 2953 cases and 5857 controls, mean age 70 years, and 65% men. At 1‐year follow‐up the primary outcome occurred in 1154 (39%) cases and 1826 (31%) matched controls, yielding an adjusted hazard ratio (HR) of 1.30 (95% CI 1.21–1.40). This increased risk was observed for both HF hospitalization (30% vs. 23%, HR 1.35 [1.24–1.47]) and all‐cause death (19% vs. 15%, HR 1.21 [1.08–1.34]). Conclusions: In this nested case–control study derived from a nationwide cohort of amiodarone‐treated HF patients, new‐onset thyroid dysfunction was associated with a 30% higher risk of a composite of HF hospitalization and death within 1 year.
- 5 February 2025
- Published by Elsevier in JACC: Heart Failure
- Vol. 13 (3) , 483-493
Disparities Among Immigrants and Native Patients in Denmark With New-Onset Heart Failure With Reduced Ejection Fraction
- 5 February 2025
- Published by Elsevier in JACC: Heart Failure
- Vol. 13 (3) , 483-493
Disparities Among Immigrants and Native Patients in Denmark With New-Onset Heart Failure With Reduced Ejection Fraction
- Open Access
- 12 December 2022
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (2) , 291-299
Incidence of thyroid dysfunction following initiation of amiodarone treatment in patients with and without heart failure: a nationwide cohort study
Aims: Thyroid dysfunction is considered the most frequent complication to amiodarone treatment, but data on its occurrence outside clinical trials are sparse. The present study aimed to examine the incidence of thyroid dysfunction following initiation of amiodarone treatment in a nationwide cohort of patients with and without heart failure (HF).Methods and results: In Danish registries, we identified all patients with first-time amiodarone treatment during the period 2000–18, without prior thyroid disease or medication. The primary outcome was a composite of thyroid diagnoses and initiation of thyroid drugs. Outcomes were assessed at 1-year follow-up, and for patients free of events in the first year, in a landmark analysis for the subsequent 5 years. We included 43 724 patients with first-time amiodarone treatment, of whom 16 939 (38%) had HF. At 1-year follow-up, the cumulative incidence and adjusted hazard ratio (HR) of the primary outcome were 5.3% and 1.37 (95% confidence interval 1.25–1.50) in patients with a history of HF and 4.2% in those without HF (reference). In the 1-year landmark analysis, the subsequent 5-year cumulative incidences and adjusted HRs of the primary outcome were 5.3% (reference) in patients with 1-year accumulated dose 175 mg).Conclusion: Among patients who initiated amiodarone treatment, around 5% had thyroid dysfunction at 1-year follow-up, with a slightly higher incidence in those with HF. A dose–response relationship was observed between the 1-year accumulated amiodarone dose and the subsequent 5-year cumulative incidence of thyroid dysfunction.
- 12 December 2022
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (2) , 291-299
Open AccessIncidence of thyroid dysfunction following initiation of amiodarone treatment in patients with and without heart failure: a nationwide cohort study
Aims: Thyroid dysfunction is considered the most frequent complication to amiodarone treatment, but data on its occurrence outside clinical trials are sparse. The present study aimed to examine the incidence of thyroid dysfunction following initiation of amiodarone treatment in a nationwide cohort of patients with and without heart failure (HF).Methods and results: In Danish registries, we identified all patients with first-time amiodarone treatment during the period 2000–18, without prior thyroid disease or medication. The primary outcome was a composite of thyroid diagnoses and initiation of thyroid drugs. Outcomes were assessed at 1-year follow-up, and for patients free of events in the first year, in a landmark analysis for the subsequent 5 years. We included 43 724 patients with first-time amiodarone treatment, of whom 16 939 (38%) had HF. At 1-year follow-up, the cumulative incidence and adjusted hazard ratio (HR) of the primary outcome were 5.3% and 1.37 (95% confidence interval 1.25–1.50) in patients with a history of HF and 4.2% in those without HF (reference). In the 1-year landmark analysis, the subsequent 5-year cumulative incidences and adjusted HRs of the primary outcome were 5.3% (reference) in patients with 1-year accumulated dose 175 mg).Conclusion: Among patients who initiated amiodarone treatment, around 5% had thyroid dysfunction at 1-year follow-up, with a slightly higher incidence in those with HF. A dose–response relationship was observed between the 1-year accumulated amiodarone dose and the subsequent 5-year cumulative incidence of thyroid dysfunction.